UY37206A - THREE-SPECIFIC AND / OR TRIVAL UNION PROTEINS - Google Patents

THREE-SPECIFIC AND / OR TRIVAL UNION PROTEINS

Info

Publication number
UY37206A
UY37206A UY0001037206A UY37206A UY37206A UY 37206 A UY37206 A UY 37206A UY 0001037206 A UY0001037206 A UY 0001037206A UY 37206 A UY37206 A UY 37206A UY 37206 A UY37206 A UY 37206A
Authority
UY
Uruguay
Prior art keywords
proteins
trival
specific
binding
polypeptides
Prior art date
Application number
UY0001037206A
Other languages
Spanish (es)
Inventor
Yang Zhi-Yong
Gary Nabel
Lan Wu
Edward Seung
Jochen Beninga
Ercole Rao
Dirk Leuschner Wulf
Christian Beil
Christian Lange
Carsten Corvey
Ronnie Wei
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58464471&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY37206(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of UY37206A publication Critical patent/UY37206A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

La descripción proporciona proteínas de unión triespecíficas y/o trivalentes que comprenden cuatro cadenas de polipéptidos que forman tres sitios de unión con antígenos que específicamente unen una o varias proteínas blanco, en donde un primer par de polipéptidos que forman la proteína de unión posee dominios variables duales que tienen una orientación cruzada y en donde un segundo par de polipéptidos que forman la proteína de unión posee un dominio variable simple. La descripción también proporciona métodos para preparar proteínas de unión triespecíficas y/o trivalentes y usos de tales proteínas de uniónThe description provides trispecific and / or trivalent binding proteins comprising four polypeptide chains that form three binding sites with antigens that specifically bind one or more white proteins, wherein a first pair of polypeptides that form the binding protein has variable domains. Duals that have a cross-orientation and where a second pair of polypeptides that form the binding protein has a simple variable domain. The description also provides methods for preparing trypecific and / or trivalent binding proteins and uses of such binding proteins.

UY0001037206A 2016-04-13 2017-04-18 THREE-SPECIFIC AND / OR TRIVAL UNION PROTEINS UY37206A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662322036P 2016-04-13 2016-04-13
US201662331191P 2016-05-03 2016-05-03
US201662412187P 2016-10-24 2016-10-24
EP17305298 2017-03-17

Publications (1)

Publication Number Publication Date
UY37206A true UY37206A (en) 2017-11-30

Family

ID=58464471

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037206A UY37206A (en) 2016-04-13 2017-04-18 THREE-SPECIFIC AND / OR TRIVAL UNION PROTEINS

Country Status (23)

Country Link
US (2) US10882922B2 (en)
EP (1) EP3443006B1 (en)
JP (1) JP7195929B2 (en)
KR (1) KR20180134378A (en)
CN (1) CN109476732B (en)
AU (1) AU2017248671A1 (en)
BR (1) BR112018070998A2 (en)
CA (1) CA3020633A1 (en)
CL (1) CL2018002883A1 (en)
CO (1) CO2018012107A2 (en)
CR (1) CR20180539A (en)
DO (1) DOP2018000225A (en)
EA (1) EA201892312A1 (en)
IL (1) IL262241B1 (en)
MA (1) MA44670B1 (en)
MX (1) MX2018012566A (en)
PE (1) PE20190128A1 (en)
PH (1) PH12018502182A1 (en)
PT (1) PT3443006T (en)
SG (1) SG11201808911SA (en)
TW (1) TWI788286B (en)
UY (1) UY37206A (en)
WO (1) WO2017180913A2 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI671315B (en) * 2011-03-28 2019-09-11 法商賽諾菲公司 Dual variable region antibody-like binding proteins having cross-over binding region orientation
AR106188A1 (en) 2015-10-01 2017-12-20 Hoffmann La Roche ANTI-CD19 HUMANIZED HUMAN ANTIBODIES AND METHODS OF USE
CR20180288A (en) 2015-10-25 2018-09-11 Us Health THREE-SPECIFIC AND / OR TRIVALENT UNION PROTEINS FOR THE PREVENTION OR TREATMENT OF HIV INFECTION
IL262241B1 (en) * 2016-04-13 2024-01-01 Sanofi Sa Trispecific and/or trivalent binding proteins with a crossover dual variable domain arm and a traditional antibody fab arm, pharmaceutical composition comprising said binding proteins and their uses in preventing and/or treating cancer or inflammatory diseases
FI3443006T3 (en) 2016-04-13 2023-10-23 Sanofi Sa Trispecific and/or trivalent binding proteins
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
JP7304288B2 (en) 2017-02-17 2023-07-06 サノフイ Multispecific binding molecules with specificity for dystroglycan and laminin-2
US10626169B2 (en) 2017-02-17 2020-04-21 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
WO2018156740A1 (en) 2017-02-24 2018-08-30 Macrogenics, Inc. Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
EP4249068A3 (en) 2017-10-10 2023-11-22 Sanofi Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
TWI829658B (en) * 2017-11-01 2024-01-21 瑞士商赫孚孟拉羅股份公司 Bispecific 2+1 contorsbodies
EP3713959A1 (en) * 2017-11-21 2020-09-30 Innate Pharma Multispecific antigen binding proteins
CN109957026A (en) * 2017-12-22 2019-07-02 成都恩沐生物科技有限公司 Covalent multi-specificity antibody
SG11202006410WA (en) * 2018-01-12 2020-08-28 Genzyme Corp Methods for the quantitation of polypeptides
MX2020008489A (en) 2018-02-15 2020-09-25 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease.
WO2019166650A1 (en) * 2018-03-02 2019-09-06 Cdr-Life Ag Trispecific antigen binding proteins
US11555070B2 (en) * 2018-03-08 2023-01-17 Phanes Therapeutics, Inc. Anti-claudin 18.2 antibodies and uses thereof
US20210009711A1 (en) * 2018-03-14 2021-01-14 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
JP2021519072A (en) * 2018-03-27 2021-08-10 システィミューン， インク．Ｓｙｓｔｉｍｍｕｎｅ， Ｉｎｃ． Guidance and navigation control proteins and their production and usage
US10654944B2 (en) * 2018-04-10 2020-05-19 Y-Biologics Inc. Cell engaging binding molecules
CN112384243A (en) * 2018-04-17 2021-02-19 英温拉公司 Trivalent trispecific antibody constructs
CA3109513A1 (en) * 2018-08-23 2020-02-27 Regeneron Pharmaceuticals, Inc. Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof
AU2019357467A1 (en) * 2018-10-09 2021-05-27 Sanofi Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection
CN111153988B (en) * 2018-11-08 2022-11-04 中国科学院上海巴斯德研究所 Broad-spectrum neutralizing monoclonal antibody against enterovirus D68
SG11202106525TA (en) 2018-12-24 2021-07-29 Sanofi Sa Multispecific binding proteins with mutant fab domains
BR112021012337A2 (en) 2018-12-24 2021-09-14 Sanofi MULTISPECIFIC BINDING PROTEINS BASED ON PSEUDOFAB
EP3674316A1 (en) 2018-12-24 2020-07-01 Sanofi Multispecific binding proteins with mutant fab domains
JP2022521183A (en) * 2019-02-20 2022-04-06 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル A virus-encoded, regulatory T (CATVERT) or NK cell (CATVERN) linker that targets cancer
TW202104274A (en) 2019-04-09 2021-02-01 法商賽諾菲公司 Trispecific and/or trivalent binding proteins for treatment of hiv infection
US11613576B2 (en) * 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
AU2020272839A1 (en) 2019-04-09 2021-12-02 Sanofi Trispecific binding proteins, methods, and uses thereof
CN112111012B (en) * 2019-06-20 2023-07-04 成都恩沐生物科技有限公司 Covalent multispecific antibodies
EP3996747A4 (en) * 2019-07-11 2023-08-16 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (tslp)-receptor signaling
CN113166273A (en) * 2019-07-25 2021-07-23 天境生物科技(上海)有限公司 Bifunctional molecules with IL-7 activity
MX2022004881A (en) 2019-10-25 2022-05-16 Sanofi Sa Methods for analyzing chain mispairing in multispecific binding proteins.
EP4054646A1 (en) * 2019-11-05 2022-09-14 Regeneron Pharmaceuticals, Inc. N-terminal scfv multispecific binding molecules
IL295896A (en) 2020-02-26 2022-10-01 Biograph 55 Inc C19 c38 bispecific antibodies
TW202146463A (en) 2020-03-05 2021-12-16 法商賽諾菲公司 Protease-processed molecules
JP2023519699A (en) * 2020-03-30 2023-05-12 サノフイ split CH2 domain
EP4168448A1 (en) * 2020-06-23 2023-04-26 F. Hoffmann-La Roche AG Agonistic cd28 antigen binding molecules targeting her2
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
MX2023003214A (en) * 2020-09-18 2023-05-24 Regeneron Pharma Antigen-binding molecules that bind cd38 and/or cd28, and uses thereof.
IL308733A (en) 2021-05-27 2024-01-01 Sanofi Sa Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY
US20230203199A1 (en) * 2021-09-29 2023-06-29 Modex Therapeutics Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof
WO2023060277A1 (en) * 2021-10-08 2023-04-13 Arbele Limited Composition of multispecific antibodies targeting cdh17-expressing tumors and method of making and using thereof
TW202334204A (en) * 2021-12-21 2023-09-01 美商莫德斯醫療公司 Conditionally activated antigen binding polypeptide complexes and methods of use thereof
WO2023155844A1 (en) * 2022-02-16 2023-08-24 上海优替济生生物医药有限公司 Affinity-matured anti-cd40 antibody
US20240117030A1 (en) * 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof
TW202400660A (en) 2022-05-06 2024-01-01 瑞士商伊克諾斯科學公司 Cd3/bcma/cd38 trispecific antibodies
WO2023227790A1 (en) 2022-05-27 2023-11-30 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
WO2023246911A1 (en) * 2022-06-24 2023-12-28 北京可瑞生物科技有限公司 T cell receptor-based bispecific polypeptide molecule and use thereof
WO2024027828A1 (en) * 2022-08-05 2024-02-08 Chimagen Biosciences, Ltd Multi-specific antibodies targeting a dimerizable tumor antigen and an immunostimulatory antigen

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0308936B1 (en) 1987-09-23 1994-07-06 Bristol-Myers Squibb Company Antibody heteroconjugates for the killing of HIV-infected cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
EP2706116A1 (en) * 2001-01-17 2014-03-12 Emergent Product Development Seattle, LLC Binding domain-immunoglobulin fusion proteins
CN1294148C (en) * 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 Single-stranded cyctic trispecific antibody
AU2004252171B2 (en) 2003-06-27 2011-04-21 Biogen Ma Inc. Modified binding molecules comprising connecting peptides
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
CN100376599C (en) 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 Recombining single chained three specific antibodies of anti CCA, anti CD 3, anti CD 28 through genetic engineering
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
BRPI0913406A2 (en) * 2008-06-03 2018-01-09 Abbott Lab double variable domain immunoglobulins and their uses
CN103403026B (en) 2009-09-25 2016-05-11 美国政府(由卫生和人类服务部的部长所代表) HIV-1 neutralizing antibody and uses thereof
JP6093696B2 (en) 2010-06-09 2017-03-08 ゲンマブ エー／エス Antibody against human CD38
JOP20210044A1 (en) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-cd38 antibodies
TWI671315B (en) 2011-03-28 2019-09-11 法商賽諾菲公司 Dual variable region antibody-like binding proteins having cross-over binding region orientation
WO2012154312A1 (en) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
CN107936121B (en) 2011-05-16 2022-01-14 埃泰美德(香港)有限公司 Multispecific FAB fusion proteins and methods of use thereof
MX358099B (en) 2011-05-17 2018-08-06 Univ Rockefeller Human immunodeficiency virus neutralizing antibodies adn methods of use thereof.
CN104080805B (en) 2011-11-07 2017-02-22 美国政府健康及人类服务部 Neutralizing gp41 antibodies and their use
CA2858716C (en) 2011-12-08 2021-10-12 Peter D. Kwong Neutralizing antibodies to hiv-1 and their use
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
JOP20200236A1 (en) 2012-09-21 2017-06-16 Regeneron Pharma Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
CN104968685A (en) * 2012-09-25 2015-10-07 格兰马克药品股份有限公司 Purification of hetero-dimeric immunoglobulins
US20140213772A1 (en) * 2012-12-28 2014-07-31 Abbvie, Inc. Cross-over dual variable domain immunoglobulin constructs
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
EP2948475A2 (en) * 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
JP6133444B2 (en) * 2013-02-26 2017-05-24 ロシュ グリクアート アーゲー Bispecific T cell activation antigen binding molecule
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
BR112015023557A2 (en) 2013-03-15 2017-10-24 Abbvie Inc specific dual binding proteins directed against tnfa
SG11201603244VA (en) 2013-11-04 2016-05-30 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
US9822186B2 (en) * 2014-03-28 2017-11-21 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
BR112017004270B1 (en) 2014-09-04 2023-03-07 Stemcell Technologies Inc METHOD OF ACTIVATION OF T CELLS OR NK CELLS
MA40801A1 (en) * 2015-01-23 2018-07-31 Sanofi Sa Anti-cd3 antibody, anti-cd123 antibody and bispecific antibodies binding specifically to cd3 and / or cd123
WO2016196740A1 (en) 2015-06-02 2016-12-08 The Rockefeller University Tri-specific antibodies for hiv therapy
BR112018005741A2 (en) 2015-09-22 2018-10-09 Univ Pennsylvania T-cell redirection method to treat HIV infection
CR20180288A (en) 2015-10-25 2018-09-11 Us Health THREE-SPECIFIC AND / OR TRIVALENT UNION PROTEINS FOR THE PREVENTION OR TREATMENT OF HIV INFECTION
CN105837688B (en) 2015-11-20 2019-02-26 北京大学深圳研究生院 Single domain antibody and its encoding gene, immunotoxin and its encoding gene, preparation method, expression vector, application and host cell
EP3992206A1 (en) 2015-12-15 2022-05-04 Gilead Sciences, Inc. Human immunodeficiency virus neutralizing antibodies
IL262241B1 (en) 2016-04-13 2024-01-01 Sanofi Sa Trispecific and/or trivalent binding proteins with a crossover dual variable domain arm and a traditional antibody fab arm, pharmaceutical composition comprising said binding proteins and their uses in preventing and/or treating cancer or inflammatory diseases
US20230242876A1 (en) 2016-12-30 2023-08-03 Shanghai Sinobio Biotech Co., Ltd. Bifunctional molecule and use thereof
JP7304288B2 (en) 2017-02-17 2023-07-06 サノフイ Multispecific binding molecules with specificity for dystroglycan and laminin-2
US10626169B2 (en) 2017-02-17 2020-04-21 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
EP4249068A3 (en) 2017-10-10 2023-11-22 Sanofi Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
AU2019357467A1 (en) 2018-10-09 2021-05-27 Sanofi Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof

Also Published As

Publication number Publication date
BR112018070998A2 (en) 2019-02-26
MX2018012566A (en) 2019-08-05
EA201892312A1 (en) 2019-04-30
IL262241A (en) 2018-11-29
TWI788286B (en) 2023-01-01
CR20180539A (en) 2019-02-15
SG11201808911SA (en) 2018-11-29
EP3443006A2 (en) 2019-02-20
CN109476732A (en) 2019-03-15
IL262241B1 (en) 2024-01-01
WO2017180913A2 (en) 2017-10-19
EP3443006B1 (en) 2023-08-02
WO2017180913A3 (en) 2018-02-08
US20170320967A1 (en) 2017-11-09
PE20190128A1 (en) 2019-01-17
MA44670B1 (en) 2023-11-30
CL2018002883A1 (en) 2019-01-18
AU2017248671A1 (en) 2018-11-29
MA44670A (en) 2019-02-20
PT3443006T (en) 2023-10-26
CN109476732B (en) 2024-03-22
CO2018012107A2 (en) 2018-11-22
PH12018502182A1 (en) 2019-11-04
US10882922B2 (en) 2021-01-05
TW201803899A (en) 2018-02-01
CA3020633A1 (en) 2017-10-19
DOP2018000225A (en) 2019-01-31
US11192960B2 (en) 2021-12-07
JP2019522459A (en) 2019-08-15
US20210061925A1 (en) 2021-03-04
WO2017180913A9 (en) 2017-11-23
JP7195929B2 (en) 2022-12-26
KR20180134378A (en) 2018-12-18

Similar Documents

Publication Publication Date Title
UY37206A (en) THREE-SPECIFIC AND / OR TRIVAL UNION PROTEINS
CL2018001065A1 (en) Triespecific and / or trivalent binding proteins for the prevention or treatment of HIV infection
CL2019000488A1 (en) Anti-tim-3 antibodies.
ECSP18095014A (en) BISPECIFIC BINDING PROTEINS THAT BIND AN IMMUNOMODULATING PROTEIN AND A TUMOR ANTIGEN
UY37928A (en) ANTI-CD38 ANTIBODIES AND METHODS OF USE
CO2018003973A2 (en) PD-1 binding proteins and methods for using them
EA201692504A1 (en) TRISPECIFIC BINDING MOLECULES AND METHODS OF THEIR APPLICATION
BR112018067458A2 (en) antibodies to tigit
BR112017025191A2 (en) ox40 antibodies and their use
EA201890285A1 (en) ANTIBODIES AGAINST PD-1, ACTIVATED ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION
EA201891709A1 (en) ANTIGENSBINKING PROTEINS, BINDING PD-L1
CO6781527A2 (en) Antibody type binding proteins with dual variable region that have cross-linkage region orientation
CL2018002998A1 (en) Compositions comprising a coformulation of anti-pd-l1 and anti-ctla-4 antibodies
CO2019001367A2 (en) Bispecific antibody type binding proteins that specifically bind to cd3 and cd123
EA201692394A1 (en) ANTIBODIES AND ANTIGENS-BINDING FRAGMENTS, WHICH SPECIFICALLY CONNECT WITH THE PROUCH OF TAU ASSOCIATED WITH MICROTUBULES
BR112018012344A2 (en) antibodies that specifically bind to hla-dr and their uses
EA202091350A1 (en) BINDING MOLECULES SPECIFICALLY BINDING TO TAU PROTEIN
EA201992281A1 (en) BINDING MOLECULES SPECIFICALLY BINDING TO TAU PROTEIN
CR20170020A (en) VARIANTS OF PROTEIN UNIONS TO FACTOR H AND METHODS OF USE OF THESE
WO2018069871A3 (en) Anti-kras binding proteins
EA201791691A1 (en) SINGLE-DOMAIN ANTIBODIES DIRECTED TO CD1d
MX2023004804A (en) Trispecific and/or trivalent binding proteins.
AR108210A1 (en) THREE-SPECIFIC AND / OR TRIVAL UNION PROTEINS
ECSP18084491A (en) TRIESPECIFIC AND / OR TRIVALENT BINDING PROTEINS
EA202191078A3 (en) TRISSPECIFIC AND / OR TRIVALENT BINDING PROTEINS FOR PREVENTION OR TREATMENT OF HIV INFECTION

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20230612